glp 1 vs glp 1/gip GLP-1 Receptor Agonists Schematic illustration of monoagonists, dual

Current guideline-recommended therapies for DPN provide symptom relief rather than modifying the disease

Peer-reviewed data in NEJM support strong weight reduction at Week 68 for cagrilintidesemaglutide vs placebo

Over time, many see fuller muscle appearance, reduced soreness, and enhanced endurance in both training and daily life

Preclinical in vivo models have demonstrated anti-fibrotic effects of incretin receptor agonism in the heart

In turn, employers can expect reduced healthcare expenditure and enhanced productivity

Orthostatic hypotensiona sudden blood pressure dip when standingaffects roughly 1 in 10 semaglutide users in clinical trials